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Abstract
Background: To assess public preferences for colorectal cancer (CRC) surveillance tests for intermediate-risk adenomas,
using a hypothetical scenario.
Methods: Adults aged 45–54 years without CRC were identified from three General Practices in England (two in
Cumbria, one in London). A postal survey was carried out during a separate study on preferences for different first-line
CRC screening modalities (non- or full-laxative computed tomographic colonography, flexible sigmoidoscopy, or
colonoscopy). Individuals were allocated at random to receive a pack containing information on one first-line test, and
a paragraph describing CRC surveillance recommendations for people who are diagnosed with intermediate-risk
adenomas during screening. All participants received a description of two surveillance options: annual single-sample,
home-based stool testing (consistent with Faecal Immunochemical Tests; FIT) or triennial colonoscopy. Invitees were
asked to imagine they had been diagnosed with intermediate-risk adenomas, and then complete a questionnaire on
their surveillance preferences.
Results: 22.1 % (686/3,100) questionnaires were returned. 491 (15.8 %) were eligible for analysis. The majority of
participants stated a surveillance preference for the stool test over colonoscopy (60.8 % vs 31.0 %; no preference: 8.1 %;
no surveillance: 0.2 %). Women were more likely to prefer the stool test than men (66.7 % vs. 53.6 %; p = .011). The
primary reason for preferring the stool test was that it would be done more frequently. The main reason to prefer
colonoscopy was its superiority at finding polyps.
Conclusions: A majority of participants stated a preference for a surveillance test resembling FIT over colonoscopy.
Future research should test whether this translates to greater adherence in a real surveillance setting.
Trial registration: International Standard Randomised Controlled Trial Number registry, ISRCTN85697880, prospectively
registered on 25/04/2013
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Background
Since 2006, the population of England aged 60–69 years
has been invited to take part in the NHS Bowel Cancer
Screening Programme (BCSP), which has since been
extended to include people up to the age of 75 years.
Eligible individuals are offered a biennial guaiac faecal
occult blood test (gFOBt), followed by therapeutic colon-
oscopy if the initial test result is abnormal. Those who
have adenomas detected are often referred for surveil-
lance: Per current BCSP guidelines, standard practice is
for individuals who have three or more adenomas (one
of which is large; ≥1 cm), or five or more smaller
(<1 cm) adenomas to be considered high risk of develop-
ing CRC and recommended to undergo a colonoscopy
in 12 months, followed by colonoscopies at 3-year inter-
vals. Similarly, individuals who have one or more large
(≥1 cm) or 3 or 4 smaller adenomas (<1 cm) are consid-
ered to be at ‘intermediate risk’ of developing CRC, and
are referred for triennial colonoscopies [1].
Although annual colonoscopy is considered the opti-
mal surveillance test for individuals at high risk of CRC,
there are limitations to its use for surveillance of people
at intermediate risk. It is resource-intensive and low
yield; only approximately 3 % of surveillance colonos-
copies detect advanced adenomas in intermediate risk
patients [2, 3]. In addition, around 20 % of those at
intermediate risk (and even high risk) for CRC do not
attend colonoscopic surveillance [4]. Factors associated
with non-attendance of screening colonoscopy may in-
clude laxative bowel preparation [5], anxiety about the
procedure [5], expectations of pain and embarrassment
[5, 6], and perceived unpleasantness of the test [7].
Hence, there is interest in the possibility of incorporat-
ing alternative tests into surveillance in order to mitigate
these issues and improve uptake [8, 9].
One possible option is the faecal immunochemical test
for haemoglobin (FIT), which may also be more
acceptable to invitees: A previous trial randomised
screening-naïve individuals to an offer of first-line
screening with either FIT or colonoscopy and reported
higher uptake of FIT (34.2 % vs. 24.6 %, respectively)
[10]. Similarly, a recent study found that after experien-
cing both tests, patients at average risk of CRC preferred
FIT [11]. Using FIT as the primary surveillance test
could also have the advantage of reducing demand on
endoscopy services resulting from widespread adoption
of population-based CRC screening programmes [12].
However, previous studies on people’s preferences for
stool tests (not necessarily FIT) vs. colonoscopy have
been in the context of first-line screening [11, 13–17]
and to our knowledge, only one has been in the context
of surveillance [18]. Furthermore, it is uncertain how
FIT performs and compares to colonoscopy for follow-
up of patients diagnosed with intermediate risk aden-
omas, in terms of sensitivity and specificity for advanced
adenomas and CRC. A large, pragmatic accuracy and
efficacy study (‘FIT for Follow-Up’) is in progress to
assess this. Although the accuracy of FIT has been
reported to be lower than colonoscopy as a one-off test
[19], FIT might perform comparably with triennial
colonoscopy when offered on a shorter test interval
(annually) and at a low concentration threshold (high
FIT sensitivity) [8, 9, 20, 21]. The present study is part of
a related strand of research regarding people’s prefer-
ences for the respective surveillance tests.
In a previous small-scale, qualitative ‘FIT for Follow-
Up’ study we used four focus groups to explore attitudes
towards an annual single-sample FIT vs. triennial colo-
noscopic surveillance of individuals at intermediate risk
of CRC. The principal finding was that participants with
no experience of colonoscopic surveillance had positive
perceptions of FIT [18]. Interestingly, one of the key per-
ceived benefits of annual FIT was the higher frequency of
testing; participants believed this might improve detection
of advanced lesions. Conversely, participants who preferred
triennial colonoscopy often felt that this was the more sen-
sitive test for finding polyps or cancer. However, since the
previous study was small-scale, the present study aimed to
obtain a more definitive estimate of public preferences for
these two potential surveillance tests, in a larger sample of
screening- and surveillance-naïve individuals. Each partici-
pant was asked to imagine they were at intermediate-risk
of CRC, consider the two possible surveillance options,
and state an overall preference for one method or another
on a questionnaire, along with their underlying reasons
using a multiple choice question.
Methods
Participants
The recruitment strategy has previously been reported in
full [22]. In summary, 3100 screening- and surveillance-
naïve individuals aged 45–54 years from three General
Practices in England (two in Cumbria; one in London),
were invited to participate in a survey. Exclusion
criteria were (i) a previous diagnosis of bowel cancer or
recent (i.e., in the past 6 months) diagnosis of any
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cancer; (ii) receiving regular colonoscopies; (iii) learn-
ing disability or significant cognitive decline; (iv) clinic-
ally judged to be unsuitable to participate (e.g., due to
physical or psychological difficulties). Eligibility was
determined by systematic database queries and inspec-
tion of patient records by their primary care physician.
Design and measures
This study took place as part of a larger survey that
compared people’s willingness to undergo four potential
first-line screening tests [22]. Eligible individuals were
assigned at random by household to receive a study
pack, containing a cover letter, a 12-page, double-sided
A5 information booklet (‘The Facts’ booklet) and a
three-fold, double-sided A4 leaflet (‘Test Information’
leaflet). The cover letter asked invitees to read through
the information booklet and leaflet. The Facts booklet
explained:
 The concept of screening (i.e., primarily prevention
of CRC through detection of adenomas which could
become cancers over time but could be removed by
prophylactic intervention)
 A summary of how one of four first-line screening
tests (colonoscopy, flexible sigmoidoscopy, non-
laxative computed tomographic colonography
[CTC], or full-laxative CTC) would be carried out
 Possible side-effects and complications from the test
 The chances of possible results and how they would
be disseminated
 Recommended follow-up testing where applicable
(i.e., colonoscopy following an abnormal flexible
sigmoidoscopy or CTC result)
 Sensitivity of the first-line screening test (“over
90 %” for colonoscopy and full-laxative CTC; “over
85 %” for non-laxative CTC; “over 65 %” for flexible
sigmoidoscopy)
 Treatment options if cancer is detected.
The Test Information leaflet contained a more detailed
explanation of how the first-line screening test would be
carried out, including preparation requirements, what
would happen at the hospital, any medication that would
be required (e.g., sedation in the case of colonoscopy, in
accordance with typical practice in the BCSP in England),
test duration, and possible after-effects.
Information on CRC surveillance
Study packs also included a standardised questionnaire,
which gave participants a summary of how and why the
results of a colonoscopy could lead to a recommenda-
tion of surveillance, and information that possible
surveillance tests consisted of triennial colonoscopy
(previously described in the information booklets and
applicable leaflet) and a stool test resembling FIT (see
Additional file 1):
“Remember that if any polyps were found during the
[first line screening test], people might be offered a
colonoscopy. A colonoscopy looks at the large bowel
using a tiny camera passed through the back passage,
and requires a laxative preparation. If people have one
large or several small polyps removed during
colonoscopy, they would be considered to be at
‘intermediate risk’ of developing bowel cancer. People
at intermediate risk would be offered a follow-up test
in the future to check that no new polyps have grown.
This is called ‘polyp surveillance’. There are several
possible follow-up tests.”
Immediately after the information about surveillance,
participants were asked to imagine that they were found
to be at intermediate-risk for CRC during their initial
screening episode and asked a hypothetical question:
‘Imagine that you had a large polyp removed during a
colonoscopy and were at intermediate risk of
developing bowel cancer. If you were offered follow-up
testing to check that no new polyps have grown, which
option would you prefer?’
Response options consisted of:
A. ‘Another colonoscopy test every 3 years’
B. ‘A stool test at home every year. This would require
me to take a sample from one of my bowel motions
and post it back to a laboratory in a hygienically
sealed envelope. If this test result were abnormal, I
would be offered a colonoscopy.’
C. ‘No follow-up testing’
D. ‘No preference for any of these options’
Option B was designed to resemble the form of stool
testing that would be offered to surveillance patients
(i.e., FIT, requiring only one stool sample, as distinct
from the current gFOBT programme which requires
three samples). If participants stated a preference (i.e.,
they had chosen either option A or B), they were asked
to select the reason(s) for their preference from the
following list of options and they could choose more
than one option: ‘more frequent’; ‘more thorough’; ‘less
likely to cause side-effects’; ‘more familiar to me as I
(would) have had the test in the past’; ‘better at finding
polyps or cancer’; ‘less likely to harm me’; ‘more con-
venient’; or ‘better at showing me what is happening
during the test’. There was also an ‘other (please state)’
option. Since no validated measure of surveillance
preferences could be located, items were designed by
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members of the study team (AG, HB & CVW; see
Additional file 2). Response options were based on
recurring themes in the previous qualitative study [18].
Participants were asked to report their gender, age,
ethnicity, current employment status, and highest level
of education achieved. Postcodes were used to calculate
2010 Index of Multiple Deprivation (IMD) scores (an
area-based measure of socioeconomic deprivation) [23].
Participants were also asked whether they knew anyone
who had been diagnosed with bowel cancer and whether
they had ever had a bowel test themselves (i.e., not
limited to screening but any bowel test for any purpose).
Participants were asked to complete the questionnaire
and return it in a provided Freepost envelope (which
constituted consent), or to return the questionnaire
blank if they did not wish to participate. After 2 weeks, a
reminder letter and a replacement Freepost envelope
was issued to all non-responders. All study materials are
available in online appendices [22].
Analysis
Responses were pooled across the four randomised first-
line screening test conditions (since surveillance would
be recommended following colonoscopy and the closure
of a screening episode, irrespective of the pathway to
that point). Stated surveillance preferences and un-
derlying reasons were summarised using descriptive
statistics. Further analyses tested for differences in pref-
erences between subgroups (e.g., men and women) using
Pearson’s χ2 tests for association. Fisher’s exact test was
used to compare preferences by employment status and
education due to expected counts being less than five in
some cells. Wilson score 95 % confidence intervals (CI)
were calculated for overall preferences, preferences
within each subgroup, and reasons for preferences.
Responses to the measure of education were divided into
three groups: participants with a degree or higher degree
were categorised as “high education”, those with a lack of
formal qualifications were categorised as “low education”
and participants responding in other ways (e.g., A-levels
or BTECs) were categorised as “medium education”.
Results
Out of 3100 invitations, 686 questionnaires were returned
across the four conditions (22.1 %; n per condition: 164
to 178), of which 603 participants (19.5 %) were eligible
for the main analysis outlined elsewhere [24]. A further
28 (0.9 %) participants who did not answer the question
on surveillance preferences and 84 (2.7 %) patients with
previous bowel test experience were excluded as the
numbers were too small for subgroup analyses, result-
ing in a final sample of 491 (15.8 %). Demographic
characteristics of the sample are shown in Table 1. The
median age was 50 years (interquartile range [IQR]: 47
Table 1 Demographic statistics of respondents with a surveillance preference using a hypothetical scenario of being at intermediate
risk for CRC (n = 490)
All participants Prefer colonoscopy Prefer a home-based
stool testa
No preference p-value
(n = 490)b % (n = 152) [95 % CI] % (n = 298) [95 % CI] % (n = 40) [95 % CI]
Gender .011
Male (n = 220) 35.9 (79) [29.7, 42.4] 53.6 (118) [47.0, 60.1] 10.5 (23) [7.1, 15.2]
Female (n = 270) 27.0 (73) [22.1, 32.6] 66.7 (180) [60.8, 72.0] 6.3 (17) [4.0, 9.9]
Ethnicity .151
White-British (n = 432) 29.4 (127) [25.3, 33.9] 62.0 (268) [57.4, 66.5] 8.6 (37) [6.3, 11.6]
Non-White British (n = 49) 42.9 (21) [30.0, 56.7] 51.0 (25) [37.5, 64.4] 6.1 (3) [2.1, 16.5]
Employment status .960
Employed (n = 426) 31.7 (135) [27.5, 36.3] 60.3 (257) [55.6, 64.9] 8.0 (34) [5.8, 10.9]
Not employed/retired (n = 34) 29.4 (10) [16.8, 46.2] 64.7 (22) [47.9, 78.5] 5.9 (2) [1.6, 19.1]
Highest level of education .064
High education (n = 151) 27.8 (42) [21.3, 35.4] 61.6 (93) [53.6, 69.0] 10.6 (16) [6.6, 16.5]
Medium education (n = 234) 27.8 (65) [22.4, 33.8] 64.5 (151) [58.2, 70.4] 7.7 (18) [4.9, 11.8]
Low education (n = 24) 54.2 (13) [35.1, 72.1] 45.8 (11) [27.9, 64.9] 0.0 (0) [0.0, 13.8]
Indirect CRC experience .477
Knows someone with bowel cancer (n = 247) 29.6 (73) [24.2, 35.5] 63.2 (156) [57.0, 68.9] 7.3 (18) [4.7, 11.2]
Does not know someone with bowel cancer (n = 234) 32.5 (76) [26.8, 38.7] 58.1 (136) [51.7, 64.3] 9.4 (22) [6.3, 13.8]
aThe home-based stool test was comparable to FIT
bn varies because of missing data
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to 52) and median IMD score was 11.4 (IQR: 8.6 to
14.0). Females were more likely to respond to the ques-
tionnaire than males (25.8 % vs. 18.8 %), as were white
British individuals compared with those from other
ethnic groups (40.4 % vs. 13.4 %).Compared with non-
responders, responders were also slightly older (median
age: 50 vs. 49 years) and living in less deprived areas
(median IMD score: 11.5 vs 14.4; all p-values < .0005).
Only one participant in the final sample preferred no
follow-up testing (0.2 %) and so this category was omit-
ted from subsequent analyses. A small proportion of
participants had no preference between the options
(n = 40; 8.1 %; 95 % CI [6.1 %, 10.9 %]). The majority
stated a preference for surveillance with the stool test
(n = 298; 60.8 %; 95 % CI [56.4 %, 65.0 %]) with
colonoscopy preferred less frequently (n = 152; 31.0 %;
[27.1 %, 35.3 %]). We also found evidence of gender
differences in surveillance preferences with women more
likely to prefer the stool test than men (66.7 % vs. 53.6 %,
χ2 [2, N = 490] = 9.028, p = .011). We did not find evidence
to suggest differences in surveillance preferences by
ethnicity, employment status, level of education, or in-
direct experience of CRC (all p-values > .05).
The majority of the participants who stated a prefer-
ence for surveillance with the stool test stated that they
did so because they would be tested more frequently
(62.1 %) and the test was more convenient (51.7 %;
Table 2). A large proportion also said they believed that
it was less likely to cause side effects (39.9 %) and less
likely to cause harm (32.6 %). The majority of partici-
pants who stated a preference for colonoscopy said that
they believed the test was better at finding polyps or
cancer (77.6 %) and also more thorough (53.9 %).
Almost one in three who preferred a colonoscopy gave
the reason that they would have already had one and so
would be more familiar with the test (29.6 %; Table 2).
Discussion
This study assessed public preferences for two viable
surveillance tests that could be offered to patients at
intermediate-risk of CRC. We found that the majority of
participants stated a preference for surveillance with an
annual, single-sample, home-based stool test consistent
with FIT over triennial colonoscopy. The findings sug-
gest that participants prioritised frequency, convenience,
and lower risk of harm or side effects as the reason for
their preference for FIT, and test sensitivity and thor-
oughness as their reasons for preferring colonoscopy.
The views of participants who favoured colonoscopy
were also influenced by the perspective that they would
have already had a colonoscopy as part of the initial
screening pathway. These findings are largely consistent
with our previous qualitative study comparing attitudes
towards an annual FIT versus triennial colonoscopic sur-
veillance among individuals at intermediate risk of CRC
[18]. Stated reasons for participants’ preferences were
also similar to those of a study in which participants pre-
ferred to be screened using FIT when considering test
preparation and avoiding complications but preferred
colonoscopy when considering accuracy [11]. It was
more surprising that 16.8 % of participants who stated a
preference for FIT did so on the basis that they would
have had the test before; this may have been related to
awareness that the current BCSP is based on first-line
stool testing (which they expect to take up in future)
and that stool tests are available in other contexts (e.g.,
for diagnosis).
There were no differences by ethnicity, employment
status, education level, or for participants that knew
someone who had bowel cancer but women were more
likely than men to prefer the stool test over colonoscopy.
This latter observation is in line with previous research
showing that women have lower attendance rates for
Table 2 Reasons for surveillance test preferences using a hypothetical scenario of being at intermediate risk for CRC
Preferred a home-based stool testa Preferred colonoscopy
% (n = 298) [95 % CI] % (n = 152) [95 % CI]
Reason for preferenceb
More frequent 62.1 (185) [56.5, 67.4] 21.7 (33) [15.9, 28.9]
More convenient 51.7 (154) [46.0, 57.3] 12.5 (19) [8.2, 18.7]
Less likely to cause side-effects 39.9 (119) [34.5, 45.6] 7.2 (11) [4.1, 12.5]
Less likely to harm me 32.6 (97) [27.5, 38.1] 5.9 (9) [3.2, 10.9]
Better at finding polyps or cancer 28.9 (86) [24.0, 34.3] 77.6 (118) [70.4, 83.5]
More thorough 21.5 (64) [17.2, 26.5] 53.9 (82) [46.0, 61.7]
More familiar as I would have had the test before 16.8 (50) [13.0, 21.4] 29.6 (45) [22.9, 37.3]
Better at showing what is happening during the test 6.4 (19) [4.1, 9.8] 17.8 (27) [12.5, 24.6]
Other reasons 7.0 (21) [4.5, 10.7] 3.3 (5) [1.4, 7.5]
aThe home-based stool test was comparable to FIT
bN.B participants could select more than one reason
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screening colonoscopy than men [24, 25], that they hold
more negative expectations about the test (e.g., relating
to pain or fear of a cancer diagnosis) [25, 26], and are
more concerned about modesty, embarrassment, and
risks related to the procedure [25, 26]. In terms of col-
onoscopy experience, women report poorer tolerance
[27], more pain [28], and more discomfort [29] during
colonoscopy than men, suggesting that some of their
pre-existing concerns are well-founded. The higher pro-
portion of women stating a preference for the stool test
is also consistent with a meta-analysis of studies on FIT
in the context of screening and another recent study
that tested patients’ preferences after experiencing both
colonoscopy and FIT [11, 30].
As with the previous qualitative study, these findings
are most directly applicable to the English BCSP. In
organised CRC screening programmes, it is often neces-
sary to offer a default first-line and therapeutic test (e.g.,
first-line gFOBt and therapeutic colonoscopy) and im-
practical to offer a range of options. This also applies to
surveillance tests when they are offered to a large num-
ber of people in a centralised fashion. Previous studies
have reported several barriers to colonoscopy attendance
[5–7, 24–26] and our findings suggest that a home-
based stool test may be a more attractive alternative to
colonoscopy. Hence, the present study adds evidence
that offering annual FIT as the default surveillance
method could be an effective strategy for increasing par-
ticipation rates in the context of surveillance. Further-
more, it could also lower colonoscopy demand, which is
a significant challenge for healthcare systems in several
countries [12, 19]. In principle, the BCSP could use a
similar system for surveillance of people at intermediate
risk of CRC to that used for coordinating first-line
screening with gFOBt. Annual, single-sample FIT kits
could be posted to eligible individuals, who could then
complete the test at home and return it to a laboratory
for analysis. However, the preference for a stool test re-
sembling FIT was not universal, with about 1 in 3 partic-
ipants preferring triennial colonoscopies. One potential
method of optimising uptake of CRC surveillance would
be to offer FIT as a default test but for colonoscopic sur-
veillance to remain an option for those who persistently
decline FIT. These findings also suggest that in health-
care systems that offer a choice of tests, it would be ef-
fective to allow patients to select their preferred method.
These possible applications should be considered in
the context of current uncertainties regarding the rela-
tive sensitivity of annual FIT and triennial colonoscopy.
Higher uptake of FIT may not translate to superior
health outcomes or cost-effectiveness unless it delivers
adequate sensitivity and specificity. The results of the
FIT for Follow-Up study will address this important
question [8].
An important limitation of this study was that partici-
pants were asked to imagine that they were being offered
follow-up testing after being diagnosed as intermediate
risk of CRC. Therefore, preferences may not be repre-
sentative of individuals in a real life setting (i.e., with
people who had undergone CRC screening, including a
diagnostic colonoscopy). For example, one previous
study found that a majority of patients undergoing
colonoscopy reported that the experience was better
than expected [31]. Similarly, patients facing the pro-
spect of surveillance following screening would be older
than this sample (and would differ on related demo-
graphic characteristics e.g., employment and personal
health status). Participants in this study were recruited
on the basis of being screening-naïve but approaching
the eligible screening age, in order to assess preferences
for first-line tests without their perceptions being af-
fected by previous invitations and experience of tests as
part of the existing BCSP [22]. However, surveillance
preferences may differ to this screening-naïve sample. In
addition, although the sample was larger than the previ-
ous qualitative study, the response rate was lower than
expected, introducing a possible selection bias. Although
we observed few differences in preferences between
subgroups, the number of participants that were non-
white British, not employed or retired, and had a low
level of education was lower than in the general popula-
tion and there may have been differences that could not
be detected in this study.
Another important limitation was that participants
were only given information about the sensitivity of
colonoscopy and not the stool test. In the absence of
more definitive estimates, information on the sensitivity
of FIT could have been provided using data on its per-
formance as a one-off, first-line test [12] or a biennial
test [32]. Estimates of sensitivity for FIT are relatively
low compared with colonoscopy in this context. How-
ever, they were omitted due to being unlikely to offer a
valid approximation of the performance of FIT as a sur-
veillance test repeated over three rounds. Consequently,
participants’ perceptions of the stool test may have been
based primarily on its appearance (e.g., a non-invasive
and less thorough test may have also been perceived as
less capable of detecting adenomas) and preferences
may change in light of additional information [11].
Future research could determine whether preferences
are consistent when people are also given this informa-
tion, once more applicable estimates are available.
Furthermore, the four randomised conditions provided
slightly different information about the first-line screen-
ing tests. For example, invitees allocated to receive
literature about colonoscopy for first-line screening were
provided with extra information about the test e.g., that
it was ‘over 90 % accurate for detecting polyps and
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cancer’, whereas invitees in other conditions were given
the associated statistic for a different test (either flexible
sigmoidoscopy or a form of CTC). This meant that
participants receiving information about colonoscopy
might have had more knowledge about its capabilities,
particularly since information on accuracy of FIT as a
diagnostic test was not provided. However, although
information and measures relating to preferences for
first-line screening tests may have been distracting, when
we compared surveillance preferences across the four
conditions we did not find statistically significant differ-
ences. The numbers were small but this suggests that
the type of information participants received regarding
screening did not affect their preferences for surveil-
lance tests.
Conclusions
When asked to imagine being at intermediate risk of
CRC, individuals aged 45–54 years generally stated a
preference for an annual single-sample home-based stool
test resembling FIT over triennial colonoscopy for surveil-
lance. FIT may be a viable alternative to colonoscopy, and
may be favoured by women in particular. Future research
should consider whether this preference translates to
improved adherence in a real surveillance setting.
Additional files
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(DOCX 1099 kb)
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